Full-Time
Posted on 9/20/2025
TIL-based T-cell therapies for solid tumors
No salary listed
Philadelphia, PA, USA
In Person
LI-onsite indicates on-site requirement. No remote option.
Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.
Company Size
501-1,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
2007
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company's annual meeting of stockholders, which is anticipated to be held in June 2026. Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board. 03/20/2026 - 05:00 PM Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): (Exact Name of Registrant as Specified in Charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Securities registered pursuant to Section 12(b) of the Act: On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the "") of Iovance Biotherapeutics, Inc. (the ""), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company's annual meeting of stockholders (the "") currently anticipated to be held in June 2026. Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting. The decision to retire and not stand for re-election is not due to a disagreement between the Company and Ms. Yarno on any matter regarding the Company's operations, policies, or practices. The Company thanks Ms. Yarno for her service to the Board. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What board change did Iovance Biotherapeutics (IOVA) disclose in this 8-K? Iovance Biotherapeutics disclosed that board member Wendy Yarno will retire and not stand for re-election at the upcoming annual meeting. She will remain on the Board until that meeting, and the company expressed appreciation for her service and contributions. When will Iovance Biotherapeutics (IOVA) director Wendy Yarno retire from the Board? Wendy Yarno will retire from the Iovance Biotherapeutics Board at the company's annual meeting of stockholders, currently anticipated for June 2026. She will continue serving as a director until that meeting, providing continuity during the transition period for the Board. Did Wendy Yarno's retirement from Iovance Biotherapeutics (IOVA) involve any disagreement with the company? The company stated that Wendy Yarno's decision to retire and not stand for re-election was not due to any disagreement regarding Iovance's operations, policies, or practices. This language signals an orderly governance transition rather than a dispute-driven departure. What role did Wendy Yarno hold at Iovance Biotherapeutics (IOVA) before announcing retirement? Wendy Yarno served as a member of the Board of Directors of Iovance Biotherapeutics. She notified the Board on March 17, 2026 that she will retire and not stand for re-election at the company's anticipated June 2026 annual stockholder meeting. How did Iovance Biotherapeutics (IOVA) characterize Wendy Yarno's retirement from the Board? Iovance Biotherapeutics indicated that Wendy Yarno's retirement is a personal decision, explicitly noting no disagreement over operations, policies, or practices. The company publicly thanked her for her service, framing the change as a normal board succession event. Filing exhibits & attachments. 3 documents
Iovance Biotherapeutics reached a new 52-week high of $5.34 on Friday before closing at $5.13, up 12.01 per cent, following UBS doubling its price target to $4 from $2, though maintaining a neutral rating. Wells Fargo reaffirmed its buy recommendation with a $14 price target. The biopharmaceutical company will participate in Barclays' 28th Annual Global Healthcare Conference on 11 March, where investors will watch for business updates. Iovance reported a 5 per cent wider net loss for 2024 at $390.98 million, whilst total revenues jumped 60.6 per cent to $263.5 million. Fourth-quarter net loss narrowed 8 per cent to $71.9 million, with revenues increasing 17.6 per cent to $86.7 million year-on-year.
UBS analyst David Dai raised the price target on Iovance Biotherapeutics from $2 to $4 whilst maintaining a Neutral rating. The upgrade follows fundamental improvements in fiscal Q4 2025, though the analyst noted that Amtagvi acceleration remains uncertain. Iovance reported quarterly revenue of $86.77 million, up 17.74% year-over-year and beating estimates by $5.76 million. Full-year product revenue reached $264 million, driven by a 112% increase in Amtagvi revenue. The drug, used for advanced melanoma treatment, saw accelerated uptake across academic and community treatment centres. The commercial-stage biopharmaceutical company develops cell therapies using autologous tumour-infiltrating lymphocytes for metastatic melanoma and other solid tumour cancers.
Iovance Biotherapeutics reported 61% year-over-year revenue growth to $264 million for 2025, driven by its cancer treatment Amtagvi. Fourth-quarter product revenue reached $87 million, up 30% from the previous quarter. Amtagvi revenue increased 112% year-over-year. The biotech company achieved several regulatory milestones, including FDA Fast Track Designation for lifileucel in non-small cell lung cancer, supporting a projected 2027 launch. Clinical data showed a 50% confirmed response rate in advanced soft tissue sarcomas. The commercial-stage biopharmaceutical company develops cell therapies using autologous tumour infiltrating lymphocyte for metastatic melanoma and other solid tumour cancers. Management expressed confidence in the company's expanding pipeline and growing network of authorised treatment centres, with international market launches planned ahead.
Iovance Biotherapeutics reported approximately 30% revenue growth in Q4 2025, with product revenue reaching $87 million. Full-year 2025 revenue totalled $264 million, a 61% increase year-over-year, driven primarily by its Amtagvi product, which saw 112% growth. The company's gross margin improved to 50% in Q4 from 43% in the previous quarter, following full internalisation of manufacturing operations. Iovance ended 2025 with $303 million in cash, extending its runway into Q3 2027. The FDA granted fast track designation for Lifileucel in non-small cell lung cancer. Clinical trials in advanced soft tissue sarcomas showed a 50% confirmed response rate. The company did not provide 2026 revenue guidance and faces challenges scaling community treatment centres beyond academic institutions.